GoodRx Holdings, Inc. Announces Change in Independent Auditors

Santa Monica, CA, March 18, 2026 — GoodRx Holdings, Inc. (NASDAQ: GDRX) has announced a significant change in its independent registered public accounting firm, a development that all shareholders and investors should be aware of. This information was disclosed in the company’s latest Form 8-K filing with the Securities and Exchange Commission (SEC).

Key Highlights from the Report

• Change of Auditor: On March 14, 2026, the Audit and Risk Committee of GoodRx Holdings, Inc. approved the appointment of KPMG LLP as the company’s new independent registered public accounting firm for the fiscal year ending December 31, 2026. At the same time, the committee approved the dismissal of PricewaterhouseCoopers LLP (PwC), which had served as the company’s auditor until this decision.
• No Adverse Opinions by Former Auditor: The audit reports issued by PwC on GoodRx’s consolidated financial statements for the years ended December 31, 2025 and 2024 did not contain any adverse opinions or disclaimers of opinion. The reports were also not qualified or modified as to uncertainty, audit scope, or accounting principles.
• No Disagreements or Reportable Events: During the two most recent fiscal years and the subsequent interim period through March 14, 2026, there were no disagreements between GoodRx and PwC regarding accounting principles, financial statement disclosure, or audit scope and procedures. Furthermore, there were no “reportable events” such as material weaknesses, significant deficiencies, or disagreements that would require disclosure under SEC rules.
• No Consultations with Incoming Auditor: The company confirmed that during the relevant periods, neither GoodRx nor anyone acting on its behalf consulted with KPMG LLP regarding the application of accounting principles to a specific transaction, the type of audit opinion that might be rendered, or any matters that would be considered a disagreement or a reportable event.
• Regulatory Compliance: GoodRx provided PwC with a copy of the disclosures made in the Form 8-K and requested that PwC furnish a letter to the SEC stating whether it agreed with the statements made. PwC responded in a letter dated March 18, 2026, affirming agreement with the company’s statements.

Implications for Shareholders

The change of a company’s independent auditor is a matter of material interest for investors. Here’s why this announcement is important and potentially price-sensitive:

• Potential Market Reaction: A change in the independent registered public accounting firm can sometimes raise questions among investors regarding the company’s accounting practices, internal controls, or future financial reporting. However, GoodRx has clearly stated that the change was not due to any disagreements or reportable events, which helps mitigate negative speculation.
• Transparency and Best Practices: The company has complied with best practices by providing full disclosure, including obtaining a confirming letter from the outgoing auditor (PwC). This level of transparency is positive for investor confidence.
• Regulatory and Governance Signal: The decision was made by the Audit and Risk Committee of the Board of Directors, underlining the company’s commitment to sound governance.
• Impact on Share Value: While there is no indication of any underlying financial or control issues, changes in auditors do attract attention from analysts and institutional investors. The lack of any adverse opinions, disagreements, or reportable events should reassure shareholders, but the market may react to the headline change.

Additional Details

• Trading Symbol: GDRX
• Stock Exchange: The Nasdaq Stock Market LLC
• Company Address: 2701 Olympic Boulevard, Santa Monica, CA 90404
• Filing Date: March 18, 2026
• Fiscal Year End: December 31
• Chief Financial Officer & Treasurer: Christopher McGinnis

Conclusion

For investors and shareholders, auditor transitions are closely watched events. The absence of any negative findings or unresolved issues in this case is reassuring, but the market will be alert for any further updates. GoodRx Holdings, Inc. appears to be maintaining strong governance and transparency practices during this transition.

Disclaimer: This article is for informational purposes only and does not constitute financial or investment advice. Investors are urged to do their own research or consult with a qualified financial advisor before making any investment decisions. The information presented is based on the company’s SEC filings as of March 18, 2026, and may be subject to change.

View GoodRx Holdings, Inc. Historical chart here